Why Did Stan Druckenmiller Sell Broadcom Stock?
In Q3, legendary macro investor Stan Druckenmiller sold his entire…
Sell
48
VTAK Quote, Financials, Valuation and Earnings
Last price:
$2.04
Seasonality move
:
-25.22%
Day range:
$1.97 - $2.06
52-week range:
$1.49 - $15.68
Dividend yield:
0%
P/E ratio:
0.40x
P/S ratio:
9.40x
P/B ratio:
0.36x
Volume:
10.3K
Avg. volume:
47.5K
1-year change:
-81.34%
Market cap:
$2.5M
Revenue:
$420K
EPS (TTM):
-$34.94
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
VTAK
Catheter Precision, Inc.
|
$310K | -$0.20 | 118.75% | -11.57% | -- |
|
CATX
Perspective Therapeutics, Inc.
|
$231.1K | -$0.35 | -9.65% | -37.91% | $12.3077 |
|
INFU
InfuSystem Holdings, Inc.
|
$36.7M | $0.05 | 8.36% | 39.86% | $14.20 |
|
PMI
Picard Medical
|
-- | -- | -- | -- | -- |
|
VNRX
VolitionRX Ltd.
|
$714.1K | -$0.04 | 272.5% | -33.67% | $2.20 |
|
XTNT
Xtant Medical Holdings, Inc.
|
$30.8M | -- | -2.42% | -100% | $1.50 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
VTAK
Catheter Precision, Inc.
|
$2.00 | -- | $2.5M | 0.40x | $0.00 | 0% | 9.40x |
|
CATX
Perspective Therapeutics, Inc.
|
$2.8700 | $12.3077 | $213.4M | -- | $0.00 | 0% | 194.60x |
|
INFU
InfuSystem Holdings, Inc.
|
$8.91 | $14.20 | $181.2M | 34.07x | $0.00 | 0% | 1.34x |
|
PMI
Picard Medical
|
-- | -- | -- | -- | $0.00 | 0% | -- |
|
VNRX
VolitionRX Ltd.
|
$0.29 | $2.20 | $35.1M | -- | $0.00 | 0% | 19.58x |
|
XTNT
Xtant Medical Holdings, Inc.
|
$0.72 | $1.50 | $100.8M | 70.59x | $0.00 | 0% | 0.79x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
VTAK
Catheter Precision, Inc.
|
68.63% | 0.156 | 537.37% | 0.41x |
|
CATX
Perspective Therapeutics, Inc.
|
1.35% | 3.042 | 1.3% | 8.47x |
|
INFU
InfuSystem Holdings, Inc.
|
30.8% | 4.042 | 11.73% | 1.35x |
|
PMI
Picard Medical
|
-- | 0.000 | -- | -- |
|
VNRX
VolitionRX Ltd.
|
-48.16% | 2.723 | 15.4% | 0.04x |
|
XTNT
Xtant Medical Holdings, Inc.
|
39.2% | 3.120 | 35.76% | 1.08x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
VTAK
Catheter Precision, Inc.
|
-$320K | -$3M | -79.27% | -192.05% | -1336.73% | -$2.2M |
|
CATX
Perspective Therapeutics, Inc.
|
-$566K | -$27.9M | -37.13% | -37.63% | -13330.62% | -$18.3M |
|
INFU
InfuSystem Holdings, Inc.
|
$20.3M | $3.8M | 6.43% | 9.93% | 10.45% | $8.4M |
|
PMI
Picard Medical
|
-- | -- | -- | -- | -- | -- |
|
VNRX
VolitionRX Ltd.
|
$318.2K | -$5.1M | -- | -- | -813.17% | -$3.5M |
|
XTNT
Xtant Medical Holdings, Inc.
|
$22M | $2.5M | 2.15% | 3.78% | 7.64% | $4.2M |
Catheter Precision, Inc. vs. Competitors
-
Which has Higher Returns VTAK or CATX?
Perspective Therapeutics, Inc. has a net margin of -1037.17% compared to Catheter Precision, Inc.'s net margin of -12425.36%. Catheter Precision, Inc.'s return on equity of -192.05% beat Perspective Therapeutics, Inc.'s return on equity of -37.63%.
Company Gross Margin Earnings Per Share Invested Capital VTAKCatheter Precision, Inc.-141.59% -$1.70 $21.3M CATXPerspective Therapeutics, Inc.-270.81% -$0.35 $245.5M -
What do Analysts Say About VTAK or CATX?
Catheter Precision, Inc. has a consensus price target of --, signalling upside risk potential of 1800.06%. On the other hand Perspective Therapeutics, Inc. has an analysts' consensus of $12.3077 which suggests that it could grow by 328.84%. Given that Catheter Precision, Inc. has higher upside potential than Perspective Therapeutics, Inc., analysts believe Catheter Precision, Inc. is more attractive than Perspective Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings VTAKCatheter Precision, Inc.0 0 0 CATXPerspective Therapeutics, Inc.12 1 0 -
Is VTAK or CATX More Risky?
Catheter Precision, Inc. has a beta of -1.392, which suggesting that the stock is 239.195% less volatile than S&P 500. In comparison Perspective Therapeutics, Inc. has a beta of 1.182, suggesting its more volatile than the S&P 500 by 18.151%.
-
Which is a Better Dividend Stock VTAK or CATX?
Catheter Precision, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Perspective Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Catheter Precision, Inc. pays -- of its earnings as a dividend. Perspective Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios VTAK or CATX?
Catheter Precision, Inc. quarterly revenues are $226K, which are larger than Perspective Therapeutics, Inc. quarterly revenues of $209K. Catheter Precision, Inc.'s net income of -$2.3M is higher than Perspective Therapeutics, Inc.'s net income of -$26M. Notably, Catheter Precision, Inc.'s price-to-earnings ratio is 0.40x while Perspective Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Catheter Precision, Inc. is 9.40x versus 194.60x for Perspective Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income VTAKCatheter Precision, Inc.9.40x 0.40x $226K -$2.3M CATXPerspective Therapeutics, Inc.194.60x -- $209K -$26M
-
Which has Higher Returns VTAK or INFU?
InfuSystem Holdings, Inc. has a net margin of -1037.17% compared to Catheter Precision, Inc.'s net margin of 6.19%. Catheter Precision, Inc.'s return on equity of -192.05% beat InfuSystem Holdings, Inc.'s return on equity of 9.93%.
Company Gross Margin Earnings Per Share Invested Capital VTAKCatheter Precision, Inc.-141.59% -$1.70 $21.3M INFUInfuSystem Holdings, Inc.55.65% $0.11 $80.2M -
What do Analysts Say About VTAK or INFU?
Catheter Precision, Inc. has a consensus price target of --, signalling upside risk potential of 1800.06%. On the other hand InfuSystem Holdings, Inc. has an analysts' consensus of $14.20 which suggests that it could grow by 59.37%. Given that Catheter Precision, Inc. has higher upside potential than InfuSystem Holdings, Inc., analysts believe Catheter Precision, Inc. is more attractive than InfuSystem Holdings, Inc..
Company Buy Ratings Hold Ratings Sell Ratings VTAKCatheter Precision, Inc.0 0 0 INFUInfuSystem Holdings, Inc.5 0 0 -
Is VTAK or INFU More Risky?
Catheter Precision, Inc. has a beta of -1.392, which suggesting that the stock is 239.195% less volatile than S&P 500. In comparison InfuSystem Holdings, Inc. has a beta of 1.680, suggesting its more volatile than the S&P 500 by 68.01%.
-
Which is a Better Dividend Stock VTAK or INFU?
Catheter Precision, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. InfuSystem Holdings, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Catheter Precision, Inc. pays -- of its earnings as a dividend. InfuSystem Holdings, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios VTAK or INFU?
Catheter Precision, Inc. quarterly revenues are $226K, which are smaller than InfuSystem Holdings, Inc. quarterly revenues of $36.5M. Catheter Precision, Inc.'s net income of -$2.3M is lower than InfuSystem Holdings, Inc.'s net income of $2.3M. Notably, Catheter Precision, Inc.'s price-to-earnings ratio is 0.40x while InfuSystem Holdings, Inc.'s PE ratio is 34.07x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Catheter Precision, Inc. is 9.40x versus 1.34x for InfuSystem Holdings, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income VTAKCatheter Precision, Inc.9.40x 0.40x $226K -$2.3M INFUInfuSystem Holdings, Inc.1.34x 34.07x $36.5M $2.3M
-
Which has Higher Returns VTAK or PMI?
Picard Medical has a net margin of -1037.17% compared to Catheter Precision, Inc.'s net margin of --. Catheter Precision, Inc.'s return on equity of -192.05% beat Picard Medical's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital VTAKCatheter Precision, Inc.-141.59% -$1.70 $21.3M PMIPicard Medical-- -- -- -
What do Analysts Say About VTAK or PMI?
Catheter Precision, Inc. has a consensus price target of --, signalling upside risk potential of 1800.06%. On the other hand Picard Medical has an analysts' consensus of -- which suggests that it could fall by --. Given that Catheter Precision, Inc. has higher upside potential than Picard Medical, analysts believe Catheter Precision, Inc. is more attractive than Picard Medical.
Company Buy Ratings Hold Ratings Sell Ratings VTAKCatheter Precision, Inc.0 0 0 PMIPicard Medical0 0 0 -
Is VTAK or PMI More Risky?
Catheter Precision, Inc. has a beta of -1.392, which suggesting that the stock is 239.195% less volatile than S&P 500. In comparison Picard Medical has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock VTAK or PMI?
Catheter Precision, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Picard Medical offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Catheter Precision, Inc. pays -- of its earnings as a dividend. Picard Medical pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios VTAK or PMI?
Catheter Precision, Inc. quarterly revenues are $226K, which are larger than Picard Medical quarterly revenues of --. Catheter Precision, Inc.'s net income of -$2.3M is higher than Picard Medical's net income of --. Notably, Catheter Precision, Inc.'s price-to-earnings ratio is 0.40x while Picard Medical's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Catheter Precision, Inc. is 9.40x versus -- for Picard Medical. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income VTAKCatheter Precision, Inc.9.40x 0.40x $226K -$2.3M PMIPicard Medical-- -- -- --
-
Which has Higher Returns VTAK or VNRX?
VolitionRX Ltd. has a net margin of -1037.17% compared to Catheter Precision, Inc.'s net margin of -862.39%. Catheter Precision, Inc.'s return on equity of -192.05% beat VolitionRX Ltd.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital VTAKCatheter Precision, Inc.-141.59% -$1.70 $21.3M VNRXVolitionRX Ltd.50.73% -$0.05 -$24.7M -
What do Analysts Say About VTAK or VNRX?
Catheter Precision, Inc. has a consensus price target of --, signalling upside risk potential of 1800.06%. On the other hand VolitionRX Ltd. has an analysts' consensus of $2.20 which suggests that it could grow by 670.04%. Given that Catheter Precision, Inc. has higher upside potential than VolitionRX Ltd., analysts believe Catheter Precision, Inc. is more attractive than VolitionRX Ltd..
Company Buy Ratings Hold Ratings Sell Ratings VTAKCatheter Precision, Inc.0 0 0 VNRXVolitionRX Ltd.4 2 0 -
Is VTAK or VNRX More Risky?
Catheter Precision, Inc. has a beta of -1.392, which suggesting that the stock is 239.195% less volatile than S&P 500. In comparison VolitionRX Ltd. has a beta of 1.234, suggesting its more volatile than the S&P 500 by 23.404%.
-
Which is a Better Dividend Stock VTAK or VNRX?
Catheter Precision, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. VolitionRX Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Catheter Precision, Inc. pays -- of its earnings as a dividend. VolitionRX Ltd. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios VTAK or VNRX?
Catheter Precision, Inc. quarterly revenues are $226K, which are smaller than VolitionRX Ltd. quarterly revenues of $627.3K. Catheter Precision, Inc.'s net income of -$2.3M is higher than VolitionRX Ltd.'s net income of -$5.4M. Notably, Catheter Precision, Inc.'s price-to-earnings ratio is 0.40x while VolitionRX Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Catheter Precision, Inc. is 9.40x versus 19.58x for VolitionRX Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income VTAKCatheter Precision, Inc.9.40x 0.40x $226K -$2.3M VNRXVolitionRX Ltd.19.58x -- $627.3K -$5.4M
-
Which has Higher Returns VTAK or XTNT?
Xtant Medical Holdings, Inc. has a net margin of -1037.17% compared to Catheter Precision, Inc.'s net margin of 3.93%. Catheter Precision, Inc.'s return on equity of -192.05% beat Xtant Medical Holdings, Inc.'s return on equity of 3.78%.
Company Gross Margin Earnings Per Share Invested Capital VTAKCatheter Precision, Inc.-141.59% -$1.70 $21.3M XTNTXtant Medical Holdings, Inc.66.13% $0.01 $82.9M -
What do Analysts Say About VTAK or XTNT?
Catheter Precision, Inc. has a consensus price target of --, signalling upside risk potential of 1800.06%. On the other hand Xtant Medical Holdings, Inc. has an analysts' consensus of $1.50 which suggests that it could grow by 108.33%. Given that Catheter Precision, Inc. has higher upside potential than Xtant Medical Holdings, Inc., analysts believe Catheter Precision, Inc. is more attractive than Xtant Medical Holdings, Inc..
Company Buy Ratings Hold Ratings Sell Ratings VTAKCatheter Precision, Inc.0 0 0 XTNTXtant Medical Holdings, Inc.2 0 0 -
Is VTAK or XTNT More Risky?
Catheter Precision, Inc. has a beta of -1.392, which suggesting that the stock is 239.195% less volatile than S&P 500. In comparison Xtant Medical Holdings, Inc. has a beta of -0.077, suggesting its less volatile than the S&P 500 by 107.701%.
-
Which is a Better Dividend Stock VTAK or XTNT?
Catheter Precision, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Xtant Medical Holdings, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Catheter Precision, Inc. pays -- of its earnings as a dividend. Xtant Medical Holdings, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios VTAK or XTNT?
Catheter Precision, Inc. quarterly revenues are $226K, which are smaller than Xtant Medical Holdings, Inc. quarterly revenues of $33.3M. Catheter Precision, Inc.'s net income of -$2.3M is lower than Xtant Medical Holdings, Inc.'s net income of $1.3M. Notably, Catheter Precision, Inc.'s price-to-earnings ratio is 0.40x while Xtant Medical Holdings, Inc.'s PE ratio is 70.59x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Catheter Precision, Inc. is 9.40x versus 0.79x for Xtant Medical Holdings, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income VTAKCatheter Precision, Inc.9.40x 0.40x $226K -$2.3M XTNTXtant Medical Holdings, Inc.0.79x 70.59x $33.3M $1.3M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Is CoreWeave Stock Down So Much?
AI cloud computing business CoreWeave (NASDAQ:CRWV) has been through a…
Why Did Stan Druckenmiller Buy MercadoLibre Stock?
In Q3, billionaire Stan Druckenmiller bought about 4,620 shares of…
Stock Ideas
Buy
59
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Buy
65
Is GOOG Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 40x
Buy
51
Is GOOGL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 40x
Alerts
Buy
70
RGC alert for Jan 8
Regencell Bioscience Holdings Ltd. [RGC] is down 21.5% over the past day.
Buy
64
RVMD alert for Jan 8
Revolution Medicines, Inc. [RVMD] is up 4.61% over the past day.
Sell
38
CRNX alert for Jan 8
Crinetics Pharmaceuticals, Inc. [CRNX] is down 0.23% over the past day.
